A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy

Visual Abstract [ 68Ga]Ga-PSMA-11 ( 68Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, 68Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [177Lu]Lu-PSMA-617 (177Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of 68Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, 68Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50–0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38–0.71), 0.67 (95% CI, 0.52–0.83), and 0.59 (95% CI, 0.43–0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49–0.99), 0.76 (95% CI, 0.46–0.99), and 0.89 (95% CI, 0.67–0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66–0.85) for reader 1, 70 of 88 (0.80; 0.70–0.87) for reader 2, and 73 of 96 (0.76; 0.66–0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for 68Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility.

[1]  R. Messmann,et al.  Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial , 2022, The Journal of Nuclear Medicine.

[2]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[3]  程超,et al.  68 Ga-PSMA-11 PET-CT与全身磁共振成像诊断前列腺癌远处转移的效能比较 , 2021 .

[4]  N. Lawrentschuk,et al.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.

[5]  M. Beer,et al.  Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  H. V. van Melick,et al.  Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients. , 2020, The Journal of urology.

[7]  R. Hustinx,et al.  Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer , 2020, EJNMMI Research.

[8]  Kirsten L. Greene,et al.  Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. , 2019, AJR. American journal of roentgenology.

[9]  T. El-Diasty,et al.  68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement , 2019, Abdominal Radiology.

[10]  P. Brennan,et al.  A review of factors influencing radiologists’ visual search behaviour , 2018, Journal of medical imaging and radiation oncology.

[11]  Fabrizio Bergesio,et al.  Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Pawan K Gupta,et al.  68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study , 2017, The Journal of Nuclear Medicine.

[13]  A. Buzaid,et al.  Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. , 2014, Critical reviews in oncology/hematology.

[14]  A. Haese*,et al.  High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.

[15]  N. Bander,et al.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.

[16]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[17]  Hauptadministrator,et al.  PACKAGE INSERT , 2004 .

[18]  J. Fleiss Measuring nominal scale agreement among many raters. , 1971 .